Mercer Global Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Mercer Global Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.5K	Buy	+309	New	+$10.2K	﹤0.01%	5111

Other funds holding NAMS

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Mercer Global Advisors's NAMS Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 309 shares worth $10.5K. The stake represents ﹤0.01% of the portfolio and ranks #5111 among its holdings.

118 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Mercer Global Advisors held 309 shares of NewAmsterdam Pharma worth $10.5K as of Q2 2026.
NewAmsterdam Pharma was a new Mercer Global Advisors position in Q2 2026.
NewAmsterdam Pharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5111 holding.
118 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.